Evidence Level
Probiotics (Bifidobacterium) are a significant genus within the probiotic family, offering diverse health benefits supported by robust scientific evidence. Bifidobacterium infantis 35624 stands out as a well-researched strain, particularly for its efficacy in managing irritable bowel syndrome (IBS). A large dose-finding randomized controlled trial (RCT) demonstrated that this strain significantly alleviates IBS symptoms (Whorwell et al., 2006). Another notable strain, Bifidobacterium lactis BB-12, has garnered extensive documentation across over 400 studies, underscoring its versatility and safety in various applications.
The decline of Bifidobacterium abundance with aging is associated with increased gut inflammation and immune dysfunction. Supplementation with probiotics may help mitigate these effects by restoring a more youthful microbiome composition (Castanet et al., 2020). Recent studies have highlighted additional benefits, such as the modulation of gastrointestinal microbiota after Helicobacter pylori eradication, where probiotics reduced adverse effects and stabilized microbial balance in a multicenter trial (He et al., 2022).
Moreover, Bifidobacterium strains have shown promise in addressing other health concerns. For instance, a randomized controlled trial involving preterm neonates demonstrated that dual-strain probiotics, including Bifidobacterium bifidum and Lactobacillus acidophilus, effectively reversed gut dysbiosis by enhancing beta diversity and promoting beneficial bacteria (Sittiwong et al., 2025). These findings underscore the potential of Bifidobacterium in maintaining and restoring gut health across various populations.